More information on TAILORx
The TAILORx study met its primary and secondary endpoints. The primary endpoint was disease-free survival for patients with Recurrence Score results 11-25. Those treated with chemoendocrine therapy similar rates of clinical events to patients receiving endocrine therapy alone. Secondary endpoints for the same patient groups were distant recurrence free interval and overall survival.